Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
April 29, 2021 02:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in...
Atea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 30, 2021 16:01 ET
|
Atea Pharmaceuticals, Inc.
– Rapid advancement of AT-527 for COVID-19 – – Strategic collaboration with Roche to develop and commercialize AT-527 for COVID-19 – – Initiation of Phase 1a trial of AT-752 for dengue fever – –...
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021
March 23, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call...
Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections
March 06, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 Patients Data Supportive of AT-527 550 mg BID Dosing Regimen BOSTON, March 06, 2021 (GLOBE NEWSWIRE) -- Atea...
Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan
February 19, 2021 08:30 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO:...
Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2
February 08, 2021 16:01 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the...
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting
February 04, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the...
Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications
January 19, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
Senior executives bring proven industry experience to leadership roles in regulatory affairs and communications BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR)...
Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
December 21, 2020 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing...
Atea Pharmaceuticals Added to Russell 2000 Index
December 18, 2020 08:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has been added to the Russell 2000®...